Mereo BioPharma (MREO) Assets Average (2018 - 2026)

Mereo BioPharma (MREO) has reported Assets Average for 6 consecutive years, with $43.3 million the latest figure, recorded in Q1 2026.

• Quarterly Assets Average fell 40.2% year-over-year to $43.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.3 million (down 40.2% YoY) and the FY2025 annual result came in at $61.2 million, down 14.4% from the prior year.
• Assets Average slipped to $43.3 million in Q1 2026 per MREO's latest filing, from $49.8 million in the prior quarter.
• Over the last five years, Assets Average for MREO reached as high as $92.4 million in Q3 2024 and fell as low as $43.3 million in Q1 2026.
• A 3-year average of $66.8 million and a median of $65.5 million in 2025 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2025 — Assets Average grew 18.19% — and 2026, when it sank 40.2%.
• Year by year, Assets Average stood at $82.6 million in 2024, then tumbled by 39.74% to $49.8 million in 2025, then slipped by 13.05% to $43.3 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $43.3 million, $49.8 million, and $58.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.